CD27/TNFRSF7 Antibody (RM27-3E5) - Chimeric - Azide and BSA Free
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-75198
Recombinant Monoclonal Antibody.
Key Product Details
Species Reactivity
Mouse
Applications
ELISA, Flow Cytometry, Immunoprecipitation, Neutralization
Label
Unconjugated
Antibody Source
Recombinant Monoclonal Rabbit IgG Kappa Clone # RM27-3E5
Format
Azide and BSA Free
Concentration
1 mg/ml
Product Specifications
Immunogen
This antibody was raised by immunising mouse with mouse CD27-human IgG1 Fc fusion protein. Isolated popliteal lymph node cells were then fused with P3U1 myeloma cells to produce stable hybridomas.
Specificity
This antibody is specific for the extracellular domain of murine CD27, a TNF-receptor superfamily member.
Clonality
Monoclonal
Host
Rabbit
Isotype
IgG Kappa
Scientific Data Images for CD27/TNFRSF7 Antibody (RM27-3E5) - Chimeric - Azide and BSA Free
![ELISA: CD27/TNFRSF7 Antibody (RM27-3E5) - Chimeric - Azide and BSA Free [NBP2-75198]](https://resources.bio-techne.com/images/products/CD27-TNFRSF7-Antibody-RM27-3E5-Chimeric-ELISA-NBP2-75198-img0001.jpg "ELISA: CD27/TNFRSF7 Antibody (RM27-3E5) - Chimeric - Azide and BSA Free [NBP2-75198]")
ELISA: CD27/TNFRSF7 Antibody (RM27-3E5) - Chimeric - Azide and BSA Free [NBP2-75198]
ELISA: CD27/TNFRSF7 Antibody (RM27-3E5) - Chimeric [NBP2-75198] - Binding curves of the rabbit IgG chimeric version of the anti-CD27 (Interleukin-2 receptor subunit alpha) antibody RM27-3E5 (NBP2-75198; red line) and isotype control (anti-Fluorescein antibody; blue line) to an ELISA plate coated with CD27-Fc fusion protein at a concentration of 5 ug/ml. A 3-fold serial dilution from 10 mg/mL to 0.17 ng/ml of NBP2-75198 was used. CD70 (CD27-L) is the ligand for CD27. CD70 Fc-fusion protein was added to a 10mg/mL solution of NBP2-75198 starting at 10mg/mL, and then at 3-fold dilutions down to 0.17ng/mL (red line). A negative control assay using 4-1BB Fc-fusion protein was also performed (yellow line). For signal detection, a 1:4000 dilution of HRP-labelled anti-human IgG antibody was used.Applications for CD27/TNFRSF7 Antibody (RM27-3E5) - Chimeric - Azide and BSA Free
Application
Recommended Usage
Flow Cytometry
1:10 - 1:1000
Immunoprecipitation
1:10 - 1:500
Application Notes
This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG2a format, for improved compatibility with existing reagents, assays and techniques.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS
Format
Azide and BSA Free
Preservative
0.02% Proclin 300
Concentration
1 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C for up to 3 months. For longer storage, aliquot and store at -20C.
Background: CD27/TNFRSF7
Membrane-bound CD27 is expressed as a disulfide-linked homodimer (3). CD27 binds to the ligand CD70, a transmembrane glycoprotein that is transiently expressed on activated immune cells such as antigen presenting cells (APCs), dendritic cells (DCs), NK cells, B cells, and T cells (1,2,6,7). The receptor-ligand binding interaction leads to NFkappaB and c-Jun pathway activation which promotes immune stimulation and activation and survival of CD4+ T cells, CD8+ T cells, memory T cells, and NK cells (2,6,7). Both CD27 and CD70 are often abnormally expressed or dysregulated on malignant and cancer cells leading to immune evasion and tumor progression (7). CD27 has become a target of interest of immunotherapies for viral infections, autoimmune disease, and cancer (2). Varlilumab, an agonistic CD27 monoclonal antibody (mAB), has entered clinical trials for the treatment of hematological and solid tumor cancers (1,6). Additional clinical trials are in process that combine varlilumab with other immune checkpoint inhibitors like the programmed cell death protein-1 (PD-1) blocking mAb nivolumab (1,2). Initial results are promising, suggesting that targeting CD27, especially in combination with other therapeutics, may be a promising and effective immunotherapy for a variety of pathologies (1,2,6).
References
1. Starzer AM, Berghoff AS. New emerging targets in cancer immunotherapy: CD27 (TNFRSF7). ESMO Open. 2020;4(Suppl 3):e000629. https://doi.org/10.1136/esmoopen-2019-000629
2. Grant EJ, Nussing S, Sant S, Clemens EB, Kedzierska K. The role of CD27 in anti-viral T-cell immunity. Curr Opin Virol. 2017;22:77-88. https://doi.org/10.1016/j.coviro.2016.12.001
3. Buchan SL, Rogel A, Al-Shamkhani A. The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy. Blood. 2018;131(1):39-48. https://10.1182/blood-2017-07-741025
4. Uniprot (P26842)
5. Uniprot (P41272)
6. van de Ven K, Borst J. Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential. Immunotherapy. 2015;7(6):655-667. https://doi.org/10.2217/imt.15.32
7. Flieswasser T, Van den Eynde A, Van Audenaerde J, et al. The CD70-CD27 axis in oncology: the new kids on the block. J Exp Clin Cancer Res. 2022;41(1):12. https://doi.org/10.1186/s13046-021-02215-y
Alternate Names
CD27, TNFRSF7
Gene Symbol
CD27
Additional CD27/TNFRSF7 Products
Product Documents for CD27/TNFRSF7 Antibody (RM27-3E5) - Chimeric - Azide and BSA Free
Product Specific Notices for CD27/TNFRSF7 Antibody (RM27-3E5) - Chimeric - Azide and BSA Free
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...